- Home
- AMLX
as 04-22-2025 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 330.5M | IPO Year: | 2022 |
| Target Price: | $8.50 | AVG Volume (30 days): | 815.5K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $7.27 | Next Earning Date: | 05-08-2025 |
| Revenue: | $87,371,000 | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 31 '25 | Sell | $3.47 | 21,490 | $74,482.19 | 3,355,280 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 31 '25 | Sell | $3.48 | 9,192 | $31,954.15 | 187,969 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 31 '25 | Sell | $3.46 | 21,490 | $74,454.25 | 3,355,276 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Mar 31 '25 | Sell | $3.47 | 12,425 | $43,082.45 | 194,375 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Mar 31 '25 | Sell | $3.47 | 10,896 | $37,805.85 | 290,988 | |
| Zeiher Bernhardt G | AMLX | Director | Mar 20 '25 | Buy | $3.70 | 10,000 | $37,005.00 | 10,000 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 3 '25 | Sell | $3.17 | 4,595 | $14,549.15 | 3,355,280 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 3 '25 | Sell | $3.12 | 1,611 | $5,022.29 | 187,969 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 3 '25 | Sell | $3.15 | 4,595 | $14,483.44 | 3,355,276 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 24 '25 | Sell | $3.15 | 4,169 | $13,144.86 | 187,969 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?
BioPharma Dive
11 days ago
Amgen says Imdelltra extended survival; Parker Institute adds new leaders
Clinical Trials Arena
12 days ago
First subject dosed in Amylyx’s Phase I trial of ALS therapy
Business Wire
13 days ago
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
MT Newswires
15 days ago
Mizuho Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Raises Price Target to $7 From $3
Business Wire
20 days ago
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Insider Monkey
a month ago
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?
Simply Wall St.
2 months ago
March 2025's Top Penny Stocks To Watch
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.